Drugs / Plasma-Lyte 148
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03829488 | Jan 2018 → Jul 2021 | end stage renal failure | The University of Queensland | Completed | Met primary |
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT02721654 | Sep 2017 → Mar 2021 | — | The George Institute | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05752279 Comparator | Mar 2024 → Jul 2026 overdue | diabetic ketoacidosis | The George Institute | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma-Lyte 148 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03829488 ↗ |
| Modality | Other / unclassified | “a "balanced" crystalloid solution (Plasma-Lyte 148®)” NCT02721654 ↗ |
| Route | Intravenous | “when administered intravenously” NCT02721654 ↗ |